Proactive Investors - Run By Investors For Investors

Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) CEO Glyn Edwards caught up with Proactive Investors at the BIO CEO & Investor Conference in New York.

Edwards says the company expects to begin treating its first patient this quarter in its Phase 3 study of ridinilazol.

Summit is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.

 
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use